CLINICAL Cell Culture Ltd (C3) has announced that it has signed a heads of agreement with Sewon Cellontech Co, Ltd for the local contract manufacturing of CellSpray products in South Korea. The product is to be manufactured under licence, distributed and marketed by established third parties and is the first agreement of its type in the global roll-out of CellSpray. The contract manufacturing of CellSpray products will be by Sewon Cellontech for the Korean market. Prom-otion, clinical support and logistic services will be provided by AlloLife Corporation, C3’s Korean ReCell distributor. C3 managing director Troels Jordansen said the agreement represented an important step on the commercialisation of Cell-Spray. “We are delighted to have secured the first licence agreement as part of our global commercial roll out of CellSpray products,” he said.“The opportunity to partner with a world-class tissue engineering company like Sewon Cellontech and expand our existing colla-boration with AlloLife is a positive indication for future Korean business. We are currently working on similar agreements in three more countries and will hope to report progress on these in the near future.”
